| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
We clarified the relation between HCV gene mutations and therapeutic effect of pegylated interferon(PEG-IFN) plus ribavirin(RBV) combination therapy for chronic hepatitis C. Number of mutations in the interferon sensitivity determining region(ISDR) or interferon/rivavirin resistance determining region(IRRDR) in HCV-5A, and amino acid substation of Core70 and Core 91 were correlated to therapeutic effect. Moreover, single nucleotide polymorphisms(SNPs) located near the IL28B gene were strongly associated with a response to PEG-IFN/RBV therapy in genotype 1 patients. In recent years, HCV protease inhibitor, Telaprevir(TVR) became available for HCV, these mutations were also important to predict therapeutic effect in triple therapy of PEG-IFN+RBV+TVR.
|
